Bhaskar Pharmacy College, Yenakapally, Moinabad
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) play a crucial role in the treatment of Ankylosing spondylitis. Cost and drug toxicity frequently deter the long-term use of anti-tumor necrosis factor agents in Ankylosing spondylitis. Methodology: The trial was conducted on 50 patients with symptomatic active chronic AS who received rheumatology therapy. Every two weeks 40mg Adalimumab was administered 6 injections for subcutaneous (10 weeks). As per follow-up, they did not achieve AS response criteria by week 12. RCT was conducted on 215 patients who participated in 6 weeks & compared celecoxib, ketoprofen, and placebo were randomly allocated continuous treatment with NSAIDs or demand treatment after over half of the patients continued to improve. Results: Four clinical trials were conducted on celecoxib, Adalimumab, ketoprofen, and placebo Patients experienced early and significant improvement in pain, NSAIDs requirement, function, and several indices ASAS 20 and 40, ASAS partial remission after discontinuing injections. At weeks 12 and 48, 84% and 52% of patients showed ASAS 20 improvement. Most AS patients are at low risk of cardiovascular and gastrointestinal complications. Conclusions: A study was conducted by a rheumatologist for 215 patients a 10-week course of NSAIDS was given to patients after 10 week course there was early improvement that often lasted for 24 weeks. Continuous use of NSAIDs reduces pain without increasing toxicity.
R. Meghana, A. V. Kishore Babu, A. Srinivasa Rao, Advances Of NSAIDS In Ankylosing Spondylitis, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 9, 379-384. https://doi.org/10.5281/zenodo.8361827
10.5281/zenodo.8361827
